As a result, a post-marketing surveillance (PMS) of dabrafenib and trametinib in Japanese patients with unresectable melanoma with BRAF mutation was initiated in June 2016 to determine the safety and efficacy of dabrafenib and trametinib in a Japanese clinical setting. This evidence concerns the gene BRAF and melanoma.